Inhalant used for inhibiting coronavirus, and preparation method and application of inhalant

A coronavirus and inhalant technology, applied in the field of coronavirus-inhibiting inhalants and their preparation, can solve the problems of low target organ selectivity and narrow therapeutic window for systemic drug administration

Pending Publication Date: 2021-09-07
深圳瑞思普利生物制药有限公司 +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In summary, remdesivir injection has a good curative effect on coronaviruses, especially novel coronaviruses, but due to its narrow therapeutic window and low selectivity of target organs for systemic administration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhalant used for inhibiting coronavirus, and preparation method and application of inhalant
  • Inhalant used for inhibiting coronavirus, and preparation method and application of inhalant
  • Inhalant used for inhibiting coronavirus, and preparation method and application of inhalant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] 10mg remdesivir dry powder inhalation.

[0061] Take 10g of remdesivir micropowder, put it into No. 3 hard capsules, 10mg per capsule, 1000 capsules in total.

Embodiment 2

[0063] 1mg remdesivir dry powder inhalation.

[0064] Put 1g of remdesivir micropowder and 19g of lactose into the Turbula T2F mixer for mixing, evenly distribute it into No. 3 capsules, 20mg per capsule.

[0065] Table 1. Prescription volume

[0066] components Dosage per capsule Dosage for 1000 capsules Remdesivir 1mg 1g lactose 19mg 19g

Embodiment 3

[0068] 0.5mg remdesivir dry powder inhalation.

[0069] Put 0.5g of remdesivir micropowder and 19.5g of lactose into the Turbula T2F mixer for mixing, and evenly distribute them into No. 3 capsules, each 20mg.

[0070] Table 2. Prescription volume

[0071] components Dosage per capsule Dosage for 1000 capsules Remdesivir 0.5mg 0.5g lactose 19.5mg 19.5g

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to an inhalant used for inhibiting coronavirus, and a preparation method and application of the inhalant, and belongs to the technical field of pharmaceutical preparations. The inhalant comprises Remdesivir and/or a pharmaceutically acceptable salt thereof. According to the inhalant used for inhibiting the coronavirus, due to adoption of small-dose pulmonary administration,effective pulmonary administration concentration can be achieved when micronized or aerosolized Remdesivir is inhaled, the coronavirus, especially the novel coronavirus, can be effectively inhibited, the defects of a narrow treatment window and poor safety in the prior art are overcome, a small dosage is given for multiple times, so that the inhalant can be accumulated in the lung so as to form an effective virus inhibition effect, a curative effect can be improved or the dosage of the Remdesivir is reduced, and potential side effects are reduced.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to an inhalant for inhibiting coronavirus, its preparation method and application. Background technique [0002] Coronaviruses are enveloped, non-segmented, positive-sense, single-stranded RNA viruses with genome sizes ranging from 26 to 32 kb, the largest known RNA virus genomes. The virion has a genomic RNA and a phosphorylated nucleocapsid (N) protein wrapped in a phospholipid bilayer and covered by two different types of spike proteins: the spike glycoprotein trimer (S ) and hemagglutinin esterase (HE) present in some CoVs. The membrane (M) protein, a type III transmembrane glycoprotein, and the envelope (E) protein are located between the S protein in the viral envelope. [0003] In recent years, coronaviruses have periodically emerged around the world. The unexpected emergence of the coronavirus, its ease of transmission, and its catastrophic consequence...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/72A61K31/685A61K47/12A61K47/26A61P31/14A61P11/00
CPCA61K9/0078A61K9/0075A61K9/008A61K31/685A61K47/12A61K47/26A61P31/14A61P11/00
Inventor 胡芳李德耀陈永奇周溢谦韩飞王霆黄敏瑜康宁周晓峰
Owner 深圳瑞思普利生物制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap